Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

141. Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome

Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome McGahan L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L. Lotronex (TM): therapy for diarrhea predominant (...) irritable bowel syndrome. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2000: 4 Authors' objectives To summarise the available evidence on Lotronex (TM) for diarrhea predominant irritable bowel syndrome (IBS). Authors' conclusions Lotronex (TM) has been approved for marketing in the United States for the treatment of IBS in women whose predominant symptom is diarrhea. Lotronex (TM) has not yet

2000 Health Technology Assessment (HTA) Database.

142. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. (Abstract)

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with symptoms of abdominal pain, discomfort, and altered bowel function. Antagonists of the type 3 serotonin receptor (5-HT3) have shown promising results in the relief of IBS-associated symptoms. We aimed to confirm these findings by doing a randomised, placebo-controlled trial.We studied 647 female IBS patients (...) with diarrhoea-predominant or alternating bowel patterns (diarrhoea and constipation). 324 patients were assigned 1 mg alosetron and 323 placebo orally twice daily for 12 weeks, followed by a 4-week post-treatment period. Adequate relief of abdominal pain and discomfort was the primary endpoint; secondary endpoints included improvements in urgency, stool frequency, and stool consistency. Analysis was by intention to treat.79 (24%) of patients in the alosetron group and 53 (16%) in the placebo group dropped

2000 Lancet Controlled trial quality: predicted high

143. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials

pain and loperamide reduces diarrhoea in irritable bowel syndrome. Evid Based Med 2001;6:20-1. Indexing Status Subject indexing assigned by NLM MeSH Antidiarrheals /therapeutic use; Colonic Diseases, Functional /drug therapy; Evidence-Based Medicine; Gastrointestinal Agents /therapeutic use; Humans; Loperamide /therapeutic use; Outcome Assessment (Health Care); Parasympatholytics /therapeutic use; Psychotropic Drugs /therapeutic use; Randomized Controlled Trials as Topic AccessionNumber 12000008660 (...) in the English language were identified in the following: MEDLINE from 1966 to 1999; EMBASE from 1980 to 1999; PsycINFO from 1967 to 1999; the Cochrane Trials Register; and bibliographies from all retrieved publications. The MeSH term was 'colonic diseases, functional' and a keyword search for 'irritable', 'functional' or 'spastic' adjacent to 'bowel' or 'colon' was performed. The search was supplemented by various combinations of truncated keywords that described the type of publication such as 'random

2000 DARE.

144. Abnormal colonic fermentation in irritable bowel syndrome. (Abstract)

Abnormal colonic fermentation in irritable bowel syndrome. The cause of irritable bowel syndrome (IBS) is unknown. It may follow gastroenteritis and be associated with an abnormal gut flora and with food intolerance. Our study was designed to assess whether these factors were associated with colonic malfermentation.We carried out a crossover controlled trial of a standard diet and an exclusion diet matched for macronutrients in six female IBS patients and six female controls. During the final

1998 Lancet Controlled trial quality: uncertain

145. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. (Abstract)

Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. Irritable bowel syndrome (IBS) is a common functional bowel disorder for which there is no reliable medical treatment.To determine whether Chinese herbal medicine (CHM) is of any benefit in the treatment of IBS.Randomized, double-blind, placebo-controlled trial conducted during 1996 through 1997.Patients were recruited through 2 teaching hospitals and 5 private practices of gastroenterologists (...) , and herbalists were all blinded to treatment group.Change in total bowel symptom scale scores and global improvement assessed by patients and gastroenterologists and change in the degree of interference in life caused by IBS symptoms assessed by patients.Compared with patients in the placebo group, patients in the active treatment groups (standard and individualized CHM) had significant improvement in bowel symptom scores as rated by patients (P=.03) and by gastroenterologists (P=.001), and significant

1998 JAMA Controlled trial quality: predicted high

146. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

1998 DARE.

147. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials

Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials Talley N J, Owen B K, Boyce P, Paterson K Authors' objectives To determine whether psychological treatments are of value in irritable bowel syndrome (IBS). Searching The studies were identified by searching (...) issues in the future should lead to a better understanding of the place of psychological treatments in IBS. The authors provide a list of recommendations (Table 6), based on their results, to assist those who may wish to design future trials in this field. Bibliographic details Talley N J, Owen B K, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. American Journal of Gastroenterology 1996; 91(2): 277-286 PubMedID Indexing Status

1996 DARE.

148. Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. (Abstract)

Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. 33 patients with refractory irritable bowel syndrome were treated with four 40-minute sessions of hypnotherapy over 7 weeks. 20 improved, 11 of whom lost almost all their symptoms. Short-term improvement was maintained for 3 months without further formal treatment. Hypnotherapy in groups of up to 8 patients was as effective as individual therapy.

1989 Lancet Controlled trial quality: uncertain

149. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. (Abstract)

Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. 30 patients with severe refractory irritable-bowel syndrome were randomly allocated to treatment with either hypnotherapy or psychotherapy and placebo. The psychotherapy patients showed a small but significant improvement in abdominal pain, abdominal distension, and general well-being but not in bowel habit. The hypnotherapy patients showed a dramatic improvement in all features, the difference

1984 Lancet Controlled trial quality: uncertain

150. Controlled study of psychotherapy in irritable bowel syndrome. (Abstract)

Controlled study of psychotherapy in irritable bowel syndrome. 101 outpatients with irritable bowel syndrome were randomly allocated to two treatment groups. Both groups received the same medical treatment, but patients in one group also received dynamically oriented individual psychotherapy in ten hour-long sessions spread over 3 months. After 3 months there was a significantly greater improvement in somatic symptoms in the psychotherapy group. The difference became more pronounced a year

1983 Lancet Controlled trial quality: uncertain

151. Food hypersensitivity in irritable bowel syndrome. (Abstract)

Food hypersensitivity in irritable bowel syndrome. Food hypersensitivity as a cause of abdominal symptoms was investigated by means of exclusion diets and double-blind food provocation in patients with irritable bowel syndrome. Twenty-seven patients entered the study; nineteen complied with dietary manipulation. Food hypersensitivity as a cause of their presenting symptoms was confirmed by double-blind food provocation in only three patients, who also had evidence of associated atopic disease (...) and positive skin tests to common inhalant allergens. Evidence of minor psychiatric disorder was found in twelve of fourteen patients examined by an independent psychiatrist.

1983 Lancet Controlled trial quality: uncertain

152. Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. (Abstract)

Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Specific foods were found to provoke symptoms of irritable bowel syndrome (IBS) in 14 of 21 patients. In 6 patients who were challenged double blind the food intolerance was confirmed. No difference was detected in changes in plasma glucose, histamine, immune complexes, haematocrit, eosinophil count, or breath hydrogen excretion produced after challenge or control foods. Rectal prostaglandin E2 (PGE2), however

1982 Lancet Controlled trial quality: uncertain

153. Wheat fibre and irritable bowel syndrome. A controlled trial. (Abstract)

Wheat fibre and irritable bowel syndrome. A controlled trial. Twenty-six patients with irritable bowel syndrome entered a controlled trial of diets with a high or low wheat-fibre content. After 6 weeks on the high-wheat fibre regimen there was significant improvement in symptoms and an objective change in colonic motor activity. No such improvement occurred on the low-fibre regimen. Patients with irritable bowel syndrome should be encouraged to increase their daily intake of wheat fibre.

1977 Lancet Controlled trial quality: uncertain

154. A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome. (Abstract)

A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome. 59 outpatients with irritable bowel syndrome participated in a randomised double-blind trial. The patients in the treatment group received three biscuits daily each containing 10 g of ordinary miller's bran, whereas the patients in the control group received wheat biscuits of a similar appearance. The treatment period was 6 weeks. 52% of the patients in the treatment group noted subjective improvement (...) compared with 65% in the control group. The results of this trial do not support the routine use of miller's bran in irritable bowel syndrome.

1976 Lancet Controlled trial quality: uncertain